Outlook Therapeutics Inc. Common Stock (OTLK)
Stock · NASDAQ · Health Care
$0.488as of 10/16/2026
Price chart
Active signals
OTLK Signal Track Record
How signals performed across all stocks →What OTLK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -5.9% | 41% | September 30, 2026 |
| Bollinger Band Breakout | 21 | -8.9% | 29% | September 22, 2026 |
| Bollinger Band Breakdown | 16 | -10.3% | 38% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -5.6% | 38% | June 10, 2026 |
| Any 20-session window (baseline) | -2.0% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outl…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 17
- Website
- outlooktherapeutics.com/
Fundamentals
- 1-day range
- $0.551$0.5812
- Market cap
- $181.85M
- P/E (trailing)
- —
- P/E (forward)
- -4.67
- EPS (trailing)
- $-0.87
- Dividend yield
- —
- Beta
- 0.64
- Avg. volume
- 13.17M
- Dividend pay date
- March 18, 2019
How Outlook Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Dec 19, 2025 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Outlook Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- ARMPArmata Pharmaceuticals Inc. Common Stock$3.37▲ 9.06%Market cap $172.54MP/E —$2.75$16.34
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| ARMP Armata Pharmaceuticals Inc. Common Stock | $172.54M | — | $3.37 | ▲ 9.06% | $2.75$16.34 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 10.94M
- Total value held
- $2.22M
- Institutional holders
- 52
- Unknown4.17M
- Unknown1.97M
- Unknown710.2K
- Unknown603.6K
- Unknown477.5K
- Unknown470.0K
- Unknown275.0K
- Unknown255.2K
- Unknown232.5K
- Unknown200.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Kodiak Sciences stock rises on trial success
Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.
Kodiak Sciences stock rises on trial success. Kodiak Sciences shares surged 70% after its eye-disease drugs passed a key clinical trial. This news is specific to Kodiak Sciences and does not directly involve Outlook Therapeutics. The provided data contains no recent news or developments regarding OTLK, so this entry reflects the absence of company-specific updates.